Cellectis S.A. (NASDAQ:CLLS) Receives $7.00 Consensus Price Target from Analysts

Cellectis S.A. (NASDAQ:CLLS) has received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $7.00.

CLLS has been the subject of a number of research analyst reports. Barclays assumed coverage on shares of Cellectis in a report on Thursday, May 28th. They issued an “overweight” rating and a $9.00 price target for the company. Citizens Jmp reissued a “market outperform” rating and issued a $8.00 price objective on shares of Cellectis in a research note on Tuesday, April 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research note on Monday, April 20th.

Cellectis Stock Performance

Shares of CLLS opened at $2.83 on Monday. The company has a 50-day simple moving average of $3.53 and a 200-day simple moving average of $3.83. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $283.96 million, a PE ratio of -4.22 and a beta of 2.86. Cellectis has a 52-week low of $1.41 and a 52-week high of $5.48.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Monday, May 11th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.08. The business had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.04 million. Cellectis had a negative net margin of 89.51% and a negative return on equity of 80.66%.

Institutional Investors Weigh In On Cellectis

A number of large investors have recently added to or reduced their stakes in the business. Global Retirement Partners LLC acquired a new stake in Cellectis in the 4th quarter valued at about $34,000. Lido Advisors LLC acquired a new stake in Cellectis in the 1st quarter valued at about $32,000. Millennium Management LLC boosted its stake in shares of Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 22,080 shares during the last quarter. B Group Inc. grew its holdings in shares of Cellectis by 0.8% during the third quarter. B Group Inc. now owns 3,281,501 shares of the biotechnology company’s stock worth $9,352,000 after buying an additional 25,000 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Cellectis during the third quarter worth about $72,000. 63.90% of the stock is owned by institutional investors and hedge funds.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.